ARS Pharmaceuticals Inc (SPRY) Q3 2025 Earnings Report Preview: What To Expect
This article first appeared on GuruFocus.
ARS Pharmaceuticals Inc (NASDAQ:SPRY) is set to release its Q3 2025 earnings on Nov 10, 2025. The consensus estimate for Q3 2025 revenue is $28.74 million, and the earnings are expected to come in at -$0.47 per share. The full year 2025's revenue is expected to be $80.54 million and the earnings are expected to be -$1.65 per share. More detailed estimate data can be found on the Forecast page.
Warning! GuruFocus has detected 5 Warning Signs with SPRY.
Is SPRY fairly valued? Test your thesis with our free DCF calculator.
Revenue estimates for ARS Pharmaceuticals Inc (NASDAQ:SPRY) have increased from $79.53 million to $80.54 million for the full year 2025 and increased from $215.23 million to $229.97 million for 2026 over the past 90 days. Earnings estimates have declined from -$1.44 per share to -$1.65 per share for the full year 2025 and declined from -$0.63 per share to -$0.78 per share for 2026 over the past 90 days.
In the previous quarter of 2025-06-30, ARS Pharmaceuticals Inc's (NASDAQ:SPRY) actual revenue was $15.72 million, which beat analysts' revenue expectations of $13.78 million by 14.09%. ARS Pharmaceuticals Inc's (NASDAQ:SPRY) actual earnings were -$0.46 per share, which met analysts' earnings expectations. After releasing the results, ARS Pharmaceuticals Inc (NASDAQ:SPRY) was down by -5.04% in one day.
Based on the one-year price targets offered by 7 analysts, the average target price for ARS Pharmaceuticals Inc (NASDAQ:SPRY) is $31.14 with a high estimate of $40.00 and a low estimate of $25.00. The average target implies an upside of 280.02% from the current price of $8.20.
Based on GuruFocus estimates, the estimated GF Value for ARS Pharmaceuticals Inc (NASDAQ:SPRY) in one year is $0.00, suggesting a downside of -100% from the current price of $8.20.
Based on the consensus recommendation from 7 brokerage firms, ARS Pharmaceuticals Inc's (NASDAQ:SPRY) average brokerage recommendation is currently 1.4, indicating a \\"Buy\\" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.